CF PharmTech, Inc. executed an on-market repurchase of 67,900 H shares on 29 September 2026, paying a total of HK$0.49 million at prices ranging from HK$7.17 to HK$7.24 per share, with a volume-weighted average of HK$7.2033.

Following the transaction, the company’s issued share capital (excluding treasury shares) declined by 0.0211 % to 322.38 million shares, while treasury shares increased to 1.59 million. Total issued shares remained unchanged at 323.97 million as the repurchased stock was retained in treasury.

The buyback forms part of the repurchase mandate approved on 26 June 2026, which authorises the company to acquire up to 30.08 million shares. To date, CF PharmTech has repurchased 193,200 shares under this mandate, equivalent to 0.0642 % of the shares in issue on the mandate date.

In line with Hong Kong Stock Exchange regulations, CF PharmTech is subject to a 30-day moratorium—expiring on 29 October 2026—during which it may not issue new shares or dispose of treasury shares without prior Exchange approval.